InterCure Enters Into Definitive Share Purchase Agreement And Collaboration Agreement With Cannasoul To Advance Cannabis Science And Pharmaceutical Innovation

Agreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation

Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure

NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) ("InterCure" or the "Company") today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. ("Cannasoul"), a globally recognized pioneer in cannabis research and analytics (together, the "Agreements"). The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the Collaboration Agreement formalizes a partnership in research, development, and commercialization of evidence-based cannabis therapeutics. 

Notably, the Agreements come as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III1 - a transformative regulatory shift that could potentially unlock unprecedented opportunities for international cannabis companies such as InterCure.